# Non-inferiority Trial on Treatments in Early COVID-19

> **NCT05321394** · PHASE3 · COMPLETED · sponsor: **Azienda Ospedaliera Universitaria Integrata Verona** · enrollment: 536 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Sotrovimab
- **DRUG:** Tixagevimab Cilgavimab
- **DRUG:** Nirmatrelvir Ritonavir

## Key facts

- **NCT ID:** NCT05321394
- **Lead sponsor:** Azienda Ospedaliera Universitaria Integrata Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-07
- **Primary completion:** 2023-10-29
- **Final completion:** 2023-10-29
- **Target enrollment:** 536 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321394, "Non-inferiority Trial on Treatments in Early COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05321394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*